Skip to main content
. 2012 Jul 27;2012:bcr0320126124. doi: 10.1136/bcr.03.2012.6124

Figure 4.

Figure 4

(A) 22 months after initial injection, the temporal choroidal mass has regressed. (B) A vertical scan of the temporal lesion was done by OCT (after bevacizumab injection) and results are shown below. (C) Persistence of subretinal fluid despite two repeated injections of bevacizumab with resolution of the temporal metastatic lesion.